Direct comparison: oral THC caused anxiety and psychotic symptoms while CBD had no measurable effects | Research

The takeaway

In 16 healthy men given oral THC (10 mg) or CBD (600 mg), THC caused anxiety, psychotic symptoms, sedation, and elevated heart rate, while CBD was indistinguishable from placebo on all measures.

Read this if you want clear evidence that CBD does not produce a "high" or psychoactive effects.

CBD 600 mg: no different from placebo on any measure

What the researchers found

Sixteen healthy male volunteers received oral THC (10 mg), CBD (600 mg), or placebo in a double-blind crossover design with one-month intervals between sessions. Measurements were taken before and at 1, 2, and 3 hours post-administration.

THC produced significant anxiety, dysphoria, positive psychotic symptoms, physical and mental sedation, subjective intoxication, and increased heart rate compared to both placebo and CBD (p<0.01 for most measures).

CBD produced no significant differences from placebo on any symptomatic or physiological variable measured. The 600 mg dose was safe and well tolerated.

This was one of the cleanest head-to-head comparisons of THC and CBD effects in the same individuals, confirming their fundamentally different pharmacological profiles.

Why it matters

This study provided clear evidence that CBD does not produce the psychoactive effects associated with cannabis. By testing both compounds in the same volunteers, it eliminated the possibility that differences between compounds were due to different study populations.

The numbers in context

16 healthy males. THC 10 mg: significant anxiety, psychotic symptoms, sedation, intoxication, heart rate increase (p<0.01). CBD 600 mg: no differences from placebo on any measure.

How the study worked

Randomized, double-blind, crossover, placebo-controlled trial. 16 healthy males. Three sessions at one-month intervals. Oral THC 10 mg, CBD 600 mg, or placebo. Physiological measures and symptom ratings at baseline and 1, 2, 3 hours post-dose. AUC and peak change analyses.

What this study cannot tell us

Only male volunteers. Single-dose design. CBD at 600 mg is much higher than typical consumer doses but showed no effects, making it unlikely lower doses would. Oral administration has different pharmacokinetics than other routes.

How to read the evidence

Well-designed crossover RCT with within-subjects comparison. Clean demonstration of THC vs CBD differences. Limited by male-only sample.

When this study was published

Published in 2012. The distinct pharmacological profiles of THC and CBD have been confirmed in numerous subsequent studies.

The bigger picture

This study supported the case for CBD as a non-psychoactive therapeutic compound. The complete absence of psychoactive effects at 600 mg (a substantial dose) reinforced CBD's safety profile and distinguished it pharmacologically from THC.

Questions still open

Would higher CBD doses eventually produce measurable effects? Does CBD have subtle effects not captured by these symptom rating scales? Would the THC-CBD comparison differ in psychiatric populations?

Common questions

Does CBD get you high?

No. In this carefully controlled study, 600 mg of CBD produced absolutely no differences from placebo on measures of anxiety, intoxication, psychotic symptoms, sedation, or heart rate. CBD is pharmacologically distinct from THC.

What does THC actually do?

In this study, 10 mg oral THC caused measurable anxiety, dysphoria (unpleasant mood), positive psychotic symptoms (unusual thoughts/perceptions), sedation, subjective intoxication, and increased heart rate. All effects were statistically significant compared to both placebo and CBD.

Read the original research

Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.

Current pharmaceutical design, 18(32), 4966-79

View on PubMed ↗

Citation

Martin-Santos, R; Crippa, J A; Batalla, A; Bhattacharyya, S; Atakan, Z; Borgwardt, S; Allen, P; Seal, M; Langohr, K; Farré, M; Zuardi, A W; McGuire, P K. (2012). Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.. Current pharmaceutical design, 18(32), 4966-79.